Bevacizumab in Treating Patients With Recurrent or Progressive Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

May 31, 2009

Conditions
Brain and Central Nervous System Tumors
Interventions
BIOLOGICAL

bevacizumab

Bevacizumab 15 mg/kg every 3 weeks over 30 to 90 minutes. One cycle = 3 weeks. Treatment continues until progressive disease or unacceptable toxicity.

Trial Locations (2)

60611-2998

Hematology-Oncology Associates of Illinois, Chicago

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT00337207 - Bevacizumab in Treating Patients With Recurrent or Progressive Glioma | Biotech Hunter | Biotech Hunter